

Diansong

Slide 15: what is the different curve stands for, inter-subject variability? (Xiaoxia Chen)

Diansong

Are the PK data shown in slide 16 for individuals?
If so, how did you assign a simulated (virtual) individual to a clinical (real) individual? (David Turner)

Diansong

In slide 17(and others) are the coloured lines individual profiles or mean profiles for each of n repeated trials?
(David Turner)

Xavier

Did the approach of DLM scalar explored by specifying different value of the stomach and intestine region in the PBPK model? (Sumit Arora)

| | |
|------------------------|--|
| Xavier | To Diansong- which dissolution profile is used to fit P-PSD- pH 1, pH 3 or pH 6.8? (Kevser Sevim) |
| Xavier | For AZ examples how did you choose the permeability value used? - Did changes in the permeability value used have a large on PK profiles convoluted? (Paul Dickinson) |
| Xavier | On the slide 'Model use' where sensitivity analysis is shown, all the fitted P-PSD as well as the measured particle size distribution were well below the acceptable limit for particle size. Does this mean if you directly go with measured PSD by laser diffraction in the PBPK, this will not change the simulation results? It would be interesting to run the PBPK model just with measured PSD data (Sumit Arora) |
| Xavier/Diansong | The PSD is from in-vitro disso instead of physical measurement, correct? (Xiaoxia Chen) |

| | |
|------------------------|---|
| Xavier | Was a separate PSD limit set for the PPI conditions? was this investigated? Any experience you can share in regard to interaction with health authorities in this aspect? (Sumit Arora) |
| Xavier/Diansong | Did you use the same PBPK model for two formulations? I saw one is direct blend and the other is roller compacted. (Xiaoxia Chen) |
| Xavier/Dainsong | in the PBPK simulation you have used the surface pH model but I guess it was not important here because the dug remained highly soluble in the stomach. |
| Xavier | Noticed you stated no precipitation on gastric emptying which I think simplifies things. What evidence did you provide to support this? (Paul Dickinson) |

Christophe

Slide 10 was that intrinsic API disso or product disso in biorelevant media? (Priya Capila)

Christophe

Interesting data on slide 15, BCS IV but no food effect. Special drug delivery system? (Xiaoxia Dong)

Christophe

Why conduct in-vivo study to confirm modelling. Was this a regulatory requirement? (John Wahlich)

Christophe

Christophe, how did the z-factor perform to predict different dissolution conditions from the ones used for fitting on your two case studies ? (Xavier Pepin)

For all speakers

Is there an acceptability range that allows you to say "the model predicts well"? (Serena Zamponi)